clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Calvet Calvo X | [Treatment of Helicobacter pylori infections]. | 1998 | Gastroenterol Hepatol | pmid:9633184 |
Burman WJ et al. | AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9635911 |
Nordt SP et al. | Clarithromycin induced digoxin toxicity. | 1998 | J Accid Emerg Med | pmid:9639187 |
Gray VS | Syncopal episodes associated with cisapride and concurrent drugs. | 1998 | Ann Pharmacother | pmid:9640482 |
Grove DI et al. | Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. | 1998 | Pathology | pmid:9643503 |
Makhani S et al. | Atypical cervico-facial mycobacterial infections in childhood. | 1998 | Br J Oral Maxillofac Surg | pmid:9643597 |
Wharton JR et al. | Erythrasma treated with single-dose clarithromycin. | 1998 | Arch Dermatol | pmid:9645634 |
Shimoyama T et al. | [Antibiotic therapy in eradicating Helicobacter pylori infections]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648426 |
Kimura K and Sato K | [Recent topics on Helicobacter pylori--Historic background and problems caused by bacteria]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648427 |
Aoyama N | [Efficacy of antibiotic therapy in eradicating Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648439 |
Sato R et al. | [Problems following antibiotic therapy for eradication of Helicobacter pylori]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648440 |
Nakamura T et al. | [Topics on Helicobacter pylori (discussion)]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9648442 |
Parente F et al. | Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. | 1998 | Scand. J. Gastroenterol. | pmid:9648983 |
Moshkowitz M et al. | One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. | 1998 | Pediatrics | pmid:9651466 |
Wiedermann BL | Macrolides: clarithromycin and azithromycin. | 1998 | Pediatr Rev | pmid:9654947 |
Klein JO | Clarithromycin and azithromycin. | 1998 | Pediatr. Infect. Dis. J. | pmid:9655546 |
Amsden GW et al. | Oral cimetidine prolongs clarithromycin absorption. | 1998 | Antimicrob. Agents Chemother. | pmid:9660986 |
Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |